Company Profile

Actinobac Biomed Inc
Profile last edited on: 1/7/2019      CAGE: 5BY82      UEI: TZ2LYQ6WP918

Business Identifier: Pharmaceutical technologies derived from agents that target LFA-1
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

15 Pelham Road
Kendall Park, NJ 08824
   (732) 371-2694
Location: Single
Congr. District: 12
County: Middlesx

Public Profile

With early ties to Rutgers University, Actinobac Biomed, Inc. is organized around development of pharmaceutical based upon the natural biologic agent leukotoxin (Leukothera™), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases.. Actinobac is developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Products based upon Leukothera® are being developed for the treatment of leukemia/lymphoma, dry eye, and psoriasis. Hematologic Diseases Hematologic diseases (leukemia, lymphoma, and multiple myeloma) are cancers of white blood cells that are often deadly and difficult to treat. Preclinical efficacy studies have shown that Leukothera™ is highly effective at eliminating malignant white blood cells both under laboratory conditions and in animals. Autoimmune Diseases Autoimmune and inflammatory diseases comprise a range of disorders that are characterized by the abundant presence of chronically activated WBCs. Leukothera® specifically targets these activated WBCs without affecting healthy cells and tissues. HIV HIV infects white blood cells and can hide from our immune system within them. Current therapies can target replicating virus, but do not eliminate the HIV-infected cells. These infected white blood cells are what prevent any current drugs from curing HIV infection.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 2 NIH $2,250,118
Project Title: Targeting B-Cell Lymphoma with Leukothera

Key People / Management

  Benjamin A Belinka -- President and CEO

  Scott Kachlany -- Founder. Chair Scientific Advisory Committee